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Human Activin-A Is Expressed in the Atherosclerotic Lesion
and Promotes the Contractile Phenotype of
Smooth Muscle Cells
Marten A. Engelse, Jolanda M. Neele, Tanja A.E. van Achterberg, Benien E. van Aken,
Ron H.N. van Schaik, Hans Pannekoek, Carlie J.M. de Vries
Abstract—Activin is a member of the transforming growth factor-b superfamily, and it modulates the proliferation and
differentiation of various target cells. In this study, we investigated the role of activin in the initiation and progression
of human atherosclerosis. The expression of activin, its physiological inhibitor follistatin, and activin receptors were
assayed in human vascular tissue specimens that represented various stages of atherogenesis. In situ hybridization
experiments revealed activin mRNA in endothelial cells and macrophages and a strong induction of activin expression
in neointimal smooth muscle cells from the early onset of atherogenesis. We developed an “in situ free-activin binding
assay” by using biotinylated follistatin, which allowed us to detect bioactive activin at specific sites in atherosclerotic
lesions. The mRNAs encoding the activin receptors are expressed similarly in normal and atherosclerotic tissue, which
indicates that activin-A signaling in atherogenesis is most likely dependent on changes in growth factor concentrations
rather than on receptor levels. In vitro, activin induces the contractile, nonproliferative phenotype in cultured smooth
muscle cells, as is reflected by increased expression of smooth muscle-specific markers (SMa-actin and SM22a). Our
data provide evidence that activin induces redifferentiation of neointimal smooth muscle cells, and we hypothesize that
activin is involved in plaque stabilization. (Circ Res. 1999;85:931-939.)
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Activin belongs to the transforming growth factor-b(TGF-b) superfamily of growth factors, and it was
initially identified as a protein that induces the release of
follicle-stimulating hormone by pituitary cells.1,2 Subse-
quently, it was demonstrated that activin is involved in the
growth and differentiation of various cell types.3–8 The
glycoprotein activin consists of bA and bB chains, which are
held in homodimeric or heterodimeric configurations by
disulfide bonds. The distantly related inhibin-a subunit can
dimerize with either of the activin-b subunits, resulting in
inhibin A or inhibin B, which inhibit follicle-stimulating
hormone release from pituitary cells.9 Activin signaling is
mediated by cell-surface type I and type II activin receptors
(ActR). Two type I receptors have been described, ActR-I
(ALK-2) and ActR-IB (ALK-4), as have 2 type II receptors,
ActR-II and ActR-IIB.10 The activity of activin is regulated
by follistatin, a 34-kDa glycoprotein, which binds activin
with high affinity in equimolar complexes that are unable to
bind and activate the activin receptors.11,12
A potential role for activin in atherogenesis has been
proposed on the basis of the observation that this factor
modulates the proliferation and differentiation of several cell
types that are involved in atherogenesis, notably endothelial
cells (ECs), macrophages, and smooth muscle cells (SMCs).
Activin inhibits the propagation of human ECs,13 and it
enhances the differentiation of monocytic cells into macro-
phages.14 Most remarkably, with respect to activin function in
atherogenesis, foam cell formation of THP-1–derived mac-
rophages is inhibited.15 The effect of activin on cultured
SMCs is controversial; activin has induced DNA synthesis in
rat SMCs in some studies,16,17 whereas others reported that
activin did not affect rat SMC growth.18 In separate studies,
activin19 and follistatin20 were expressed in atherosclerotic
lesions of hyperlipidemic rabbits, and enhanced activin ex-
pression was also observed in the rat carotid artery after
balloon injury.17
In the present study, we investigated the role of activin in
human atherogenesis in detail. In situ hybridization of human
tissue specimens demonstrated the expression of activin
receptors in SMCs, ECs, and macrophages, as well as the
distinct expression of activin and follistatin in atherosclerotic
lesions. Immunohistochemical examinations revealed partial
colocalization of activin and follistatin protein; this observa-
tion prompted us to design a method to detect free, bioactive
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activin in atherosclerotic lesions. We took advantage of the
knowledge that free activin (not bound in complexes) can
associate with follistatin, and we developed a new, highly
specific “in situ free-activin binding assay” to show the
presence of significant amounts of bioactive activin in ad-
vanced atherosclerotic lesions. To reveal the function of
activin in human atherogenesis, we evaluated the expression
of activin, activin receptors, and follistatin in cultured SMCs.
Finally, we demonstrated that activin mediates the differen-
tiation of proliferating SMCs toward a contractile phenotype,
as was illustrated by the increased expression of smooth
muscle (SM)–specific genes.
Materials and Methods
Tissue Specimens
Human tissue samples were obtained from organ donors or from
patients undergoing vascular surgery with the informed consent of
relatives or the patients, according to protocols approved by the
Medical Ethical Committee of the Academic Medical Center of the
University of Amsterdam. The specimens were fixed in 3.8% vol/vol
formaldehyde in PBS and embedded in paraffin or snap-frozen in
liquid nitrogen within 5 minutes after resection. After sectioning
(5 mm) and mounting on 3-aminopropyl-triethoxysilane–coated
glass slides, the specimens were subjected to in situ hybridization,
immunohistochemistry, or the in situ free-activin binding assay.
Table 1 describes the specimens.
Immunohistochemistry
Antibody 1A4 (DAKO) recognizes SM a-actin and was used to
detect SMCs, whereas antibody HAM56 (DAKO) was used to
recognize macrophages in the sections. Activin was detected with
monoclonal antibody E4 (Serotec), and follistatin with an anti-
peptide antibody (provided by Prof S. Werner, ETH, Zurich, Swit-
zerland). Immunohistochemical examinations were performed on
5-mm paraffin sections (1A4, HAM56) or acetone-fixed cryosections
(E4, anti-follistatin) of tissue specimens. For pretreatment, the
sections were rehydrated, incubated with 0.3% hydrogen peroxide to
block endogenous peroxidase activity, and blocked with 10% vol/vol
preimmune goat serum (DAKO) in Tris-buffered saline (TBS;
10 mmol/L Tris [pH 8.0] and 150 mmol/L NaCl). Subsequently, the
sections were incubated with specific antibodies, followed by incu-
bation with biotinylated secondary antibodies, which were detected
with streptavidin-horseradish peroxidase conjugates (DAKO). ECs
were specifically recognized with Ulex europaeus lectin, which was
detected with an anti–Ulex lectin-horseradish peroxidase conjugate.
Peroxidase activity was visualized with aminoethylcarbazole and
hydrogen peroxide. After counterstaining with hematoxylin, the
sections were embedded in glycergel (Sigma).
In Situ Hybridization/RNase Protection Assay
In vitro transcription of linearized plasmid DNA was performed to
obtain radiolabeled anti-sense or sense riboprobes ([35S]-UTP for in
situ hybridization and [32P]-UTP for RNase protection [Amersham]);
see Table 2 for details on probes. The in situ hybridization assays and
RNase protection assays were performed as described previously.22
As a control for the specificity of the anti-sense riboprobes, matching
sense riboprobes were assayed for each gene; the sense probes gave
neither background nor an aspecific signal.
In Situ Free-Activin Binding Assay
Ten micrograms of purified follistatin (see Growth Factor Incubation
and Total RNA Isolation) was biotinylated for 2 hours at 0°C with 3.25
mg Sulfo-N-hydroxysuccinimide-long chain (5 mg/mL in dimethylsul-
phoxide; Pierce) in PBS at a total volume of 20 mL. The reaction was
stopped with 1 mL 1 mol/L Tris-HCl (pH 8.0). The biotinylated
follistatin was purified on a Sephadex G25 column (Pharmacia).
Subsequently, the preparation was incubated on cryosections that were
pretreated as described in Immunohistochemistry. After 2 hours of
incubation at room temperature in 250 nmol/L biotinylated follistatin
and TBS containing 1% bovine serum albumin, the sections were
washed 3 times for 2 minutes with TBS and incubated with avidin-
horseradish peroxidase conjugate, which was visualized with aminoeth-
ylcarbazole (see Immunohistochemistry).
Cell Culture
SMCs were derived from human vessel explants and originated from
the iliac artery and aorta of organ donors. The cultured SMCs were
characterized by immunofluorescence with a murine monoclonal
antibody directed against SM a-actin (1A4, DAKO), which was
detected with a Cy3-conjugated goat anti-mouse antibody (Jackson
Laboratories). With this method, the cells show uniform fibrillar
staining. The cells were used at passage 5 to 7. Cell cultures were
performed at 37°C in a humidified 5% CO2 chamber in 40%
Medium-199 with L-glutamine/L-amino acids, 40% RPMI 1640
with HEPES buffer/L-glutamine, and 20% vol/vol human serum
supplemented with penicillin, streptomycin, and Fungizone (GIBCO
BRL).
Growth Factor Incubation and Total
RNA Isolation
Purified, recombinant human activin-A [lot 15365-36(1)] and follistatin
(lot B3904) were obtained from Dr Pawson through the National
Hormone and Pituitary Program, the National Institute of Diabetes and
Digestive and Kidney Disease, the National Institute of Child Health
and Human Development, and the US Department of Agriculture
(Bethesda, Md). For growth factor incubations, SMCs were made
quiescent for 72 hours in serum-free standard medium containing 10
mg/L bovine insulin, 5.5 mg/L human transferrin, and 6.7 mg/L sodium
selenite (GIBCO BRL). Subsequently, recombinant human follistatin,
activin-A, or human serum was added to the culture medium during the
periods and at the concentrations indicated. After incubation, the cells
were subjected to total RNA isolation with Trizol reagent (GIBCO
BRL). After reprecipitation, the RNA samples were subjected to RNase
protection analyses and Northern blotting procedures.
Northern Blotting
Northern blots were made as described previously23 using Hybond N
nylon membranes (Amersham). SM a-actin mRNA was detected by
hybridization with the oligonucleotide 59-AGTGCTGTCCTCT-
TCTTCACACATA-39 and radiolabeled with [32P]-gATP (Amer-
sham). After the removal of free nucleotides on a spin column, the
probe was hybridized overnight at 50°C in 10 mmol/L sodium
phosphate (pH 6.8), 63SSC (203SSC is 0.3 mol/L sodium citrate
[pH 7.0] and 3 mol/L NaCl), 53Denhardt’s (503Denhardt’s con-
tains 1% wt/vol Ficoll, 1% wt/vol polyvinylpyrrolidone, and 1%
wt/vol bovine serum albumin), 1 mmol/L EDTA, 0.5% wt/vol SDS,
and 0.1 mg/mL salmon sperm DNA. The blot was washed for 15
minutes at 65°C, increasing the stringency to 23SSC and 0.1%
wt/vol SDS. SM22a mRNA was detected with a 1027-bp, full-length
rat cDNA (provided by Dr Shanahan, Cambridge, UK), radiolabeled
with [32P]-aATP (Amersham) using a random oligolabeling kit
(Gibco BRL), and purified on a oligonucleotide-removal column
(Qiagen). Probe hybridization in formamide was performed as
described previously.23 The blot was washed most stringently at
65°C with 0.13SSC and 0.1% wt/vol SDS.
Results
Expression of mRNA Encoding Activin, Follistatin,
and Activin Receptors in Human Vascular Tissue
We determined the expression of activin, follistatin, and
activin receptor mRNA in human vascular tissue at different
stages of atherosclerosis. The vascular specimens were char-
acterized by immunohistochemistry on consecutive sections
with specific antibodies to detect macrophages, SMCs, and
ECs (Figures 1a and 1d, 1b, and 1c, respectively). To
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TABLE 1. Pathological Specimens Used
In Situ Hybridization Assays
Sex Age, y Class Origin bA Fol I IB II IIB
Female 58 II Aorta x x x x x x
Female 50 II Art. iliaca x x x x x x
Male 12 O Art. iliaca x x x x x x
Female 76 III Art. iliaca x x x x x x
Female 76 II1V Art. iliaca x x x x x x
Female 76 III Art. iliaca x x x x x x
Female 34 III Art. iliaca x x x x x x
Female 49 V Aorta x x x x x x
Female 49 V Aorta x x x x x x
Female 52 III Aorta x x x x x x
Female 38 II Aorta x x x x x x
Female 38 II Aorta x x x x x x
Female 40 I Aorta x x x x x x
Male 69 V Art. femoralis x x x x x x
Female 27 IV Art. iliaca x x x x
Female 40 II Aorta x x x x
Female 38 II Aorta x x x x
Male 63 VI Aorta x x x x
Male 28 IV Aorta x x x x
Female 58 II1IV Aorta x x x x
Male 79 IV Art. poplitea x x x x
Male 73 II Art. thyroidia x x x x
Female 58 II Aorta x x x x
Female 76 III Art. iliaca x x x x
Male 12 O Art. iliaca x x x x
Male 73 V Art. femoralis x x x
Male 73 V Art. tibialis x x x
Female 69 III Art. carotis x x x
Male 43 III Art. femoralis x x x
Female 50 I Art. iliaca x x x
Female 50 I1III Art. iliaca x x x
Female 50 II Art. iliaca x x x
Activin and Follistatin Immunohistochemistry and Free-Activin Binding Assay
Sex Age, y Class Origin aAct aFol AB
Male 66 III Aorta x x x
Female 69 VI Aneurysm x x x
Female 58 I Aorta x x x
Female 49 IV Aorta x x x
Female 58 II Aorta x x x
Male 78 V Art. iliaca x x x
Female 45 III Aorta x x x
Male 60 VI Art. iliaca/aneurysm x x x
Female 80 VI Aorta x x x
Female 76 II Aorta x x x
Male 49 VI Aorta x x x
Female 58 II Aorta x x x
Male 56 VI Art. carotis x x x
Male 70 VI Art. carotis x x x
Class indicates the degree of atherogenesis as classified according to the guidelines issued by the American
Heart Association21; aAct, immunohistochemistry with antibodies directed against the activin bA subunit; aFol,
immunohistochemistry with antibodies directed against follistatin; and AB, in situ free-activin binding assay. All
specimens were subjected to immunohistochemistry specific for SMCs, macrophages, and ECs. Art. indicates
arteria; bA, activin-A; Fol, follistatin; I, ActR-I; II, ActR-II; IB, ActR-IB; and IIB, ActR-IIB.
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illustrate the expression of the studied genes in lesion
macrophages, we show the data from a radioactive in situ
hybridization performed in an aorta lesion containing a
substantial fibrotic core and, at the luminal side, a large
infiltrate of macrophages in Figures 1a and 1d. Both
activin-bA (Figure 1e) and follistatin (Figure 1f) are ex-
pressed by macrophages (Figure 1d); variations in expression
levels between individual cells are observed.
Only a few macrophages expressed small amounts of
ActR-I mRNA (Figure 1g), whereas ActR-IB (Figure 1h) was
expressed more homogeneously. ActR-II and ActR-IIB were
expressed by all macrophages present in the vessel wall
(Figures 1i and 1j). The type I receptors are usually expressed
at relatively low levels, which emphasizes the need to check
for the absence of background signals with corresponding
sense riboprobes. Each of the riboprobes applied in these
hybridization experiments was designed to delimit nonspe-
cific hybridization with complementary strand probes (data
not shown).
In Figure 2, an example of the mRNA expression of
activin-bA, follistatin, and activin receptors in neointimal
SMCs and ECs is shown. Activin-bA (Figure 2e) and
follistatin (Figure 2f) showed variable expression in the
neointimal SMCs (Figure 2b): SMCs with high and low
expression of these genes were randomly distributed through-
out the early lesion. ActR-I and ActR-IB mRNAs (Figure 2g
and 2h) were detected at relatively low levels in subsets of
SMCs, and both type II receptors (Figure 2i and 2j) were
expressed at high levels in all neointimal SMCs and in the
medial SMCs. In addition, activin-bB and inhibin a mRNA
expression were not detected in macrophages, SMCs, or ECs
(data not shown).
Because our studies revealed that the activin receptors
were not regulated in atherogenesis, we examined in more
detail the expression of activin-bA and follistatin mRNAs,
which encode soluble factors. In Figures 3a through 3d,
cross-sections of an early aortic fibrotic lesion are shown.
Follistatin mRNA (Figure 3c) was expressed at similar
levels in the medial and in the neointimal SMCs (Figure
3a). Activin-bA mRNA expression (Figure 3d) was, how-
ever, higher in the neointimal SMCs than the medial
SMCs. The lesion shown in Figures 3e through 3h repre-
sents an advanced aortic lesion with extensive neointima
formation and a large macrophage infiltrate (Figure 3f).
Activin-bA mRNA (Figure 3h) was detected in the media,
and its expression was considerably higher in both neoin-
timal cell types, ie, in neointimal SMCs and in macro-
phages (Figures 3e and 3f). Follistatin mRNA was readily
detected in medial SMCs and, in contrast to activin-bA
expression, was not increased in the neointima (Figures 3g
and 3h). On the basis of these data, which showed
increased mRNA expression of activin in the neointima
and similar expression of follistatin in media and neointi-
ma, we hypothesized that free activin will only be avail-
able in the atherosclerotic lesion.
TABLE 2. Detailed Information on In Situ Hybridization and
RNase Protection Riboprobes
Gene GenBank Number In Situ, bp RP, bp
Activin bA J03634 476–790 1215–1363
Activin bB M31668/ 1186–1214*
M31669 180–640* 392–640
Inhibin a M13981 125–411 125–411
Follistatin M19480 786–4306† 3234–4306†
ActR-I Z22534 419–601 419–601
ActR-IB Z22536 105–255 105–255
ActR-II M93415 597–792 597–792
ActR-IIB X77533 258–517 258–517
GAPDH M33197 z z z 480–545
RP indicates RNase protection assay; In situ, in situ hybridization; and bp,
position of the probe in the GenBank sequence in base pairs.
*Activin bB in situ riboprobe spans part of exon 1 (M31668) and part of exon
2 (M31669).
†Intron sequences are not present in riboprobes.
Figure 1. mRNA expression of activin, follistatin, and activin
receptors in an aortic lesion containing macrophages. Serial
sections of a specimen of the abdominal aorta from an organ
donor were analyzed by immunohistochemistry (a through d)
or radioactive in situ hybridization (e through j) (see Materials
and Methods). Immunohistochemistry was performed to
detect macrophages (a and d), SMCs (b), and ECs (c). Mac-
rophages are identified in a subluminal layer of the lesion (d,
enlargement of boxed area in a). SMCs are present in the
media (not shown) but absent in the macrophage infiltrate (b).
Expression of mRNA from activin, follistatin, and activin
receptors was detected with in situ hybridization using [35S]-
radiolabeled anti-sense riboprobes on serial sections of this
atherosclerotic lesion. mRNA expression of activin-bA (e), fol-
listatin (f), ActR-I (g), ActR-IB (h), ActR-II (i), and ActR-IIB (j)
was determined. Hybridization was visualized with bright-field
microscopy, which resulted in black silver grains on a pink-
red counterstain. The macrophages express activin, follistatin,
and type II receptors at relatively high levels, whereas
ActR-IB is expressed less abundantly, and ActR-I expression
is hardly detectable. L indicates lumen; M, media; Mf, mac-
rophage; and NI, neointima (double-headed arrow). Original
magnification 325 (a) or 3100 (b through j).
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Immunohistochemistry and In Situ Free-Activin
Binding Assay
In addition to the in situ hybridization experiments, the
expression of activin and follistatin protein was assayed with
specific antibodies. In agreement with the data obtained by
the in situ hybridization experiments, activin and follistatin
protein colocalized to some extent, as was shown in different
specimens (Figures 4c, 4d, 4h, 4i, 4m, and 4n). To evaluate
the presence of free activin, which is not inactivated in
complex formation with follistatin, or other presently un-
known activin-inhibiting proteins, we developed an in situ
free-activin binding assay. This assay is based on the fact that
only free, bioactive activin can bind exogenously added
follistatin. We applied biotinylated follistatin in these exper-
iments and, subsequently, bound molecules were detected
with streptavidin-conjugates.
Dose-response experiments demonstrated that the signal of
the free-activin binding assay was linear and saturable.
Competition experiments, in which an incubation of the
sections with excess unbiotinylated follistatin was performed,
resulting in complete competition of the signal, confirmed the
specificity of the assay (data not shown). In early lesions
(Figures 4a through 4e), follistatin and activin were detected
both in the media and the neointima (Figures 4c and 4d,
respectively), and the in situ free-activin binding assay
showed that no excess free activin was present (Figure 4e). In
advanced lesions, however, activin and follistatin were rela-
tively highly expressed in areas with high densities of both
macrophages and neointimal SMCs, as is shown in Figures 4f
through 4i and Figures 4k through 4n. Free activin (Figures 4j
and 4o) is detected as a fraction of total activin protein
(Figures 4i and 4n), specifically at those sites where SMCs
and macrophages are in close proximity (Figures 4f and 4g
and 4k and 4l, respectively). In conclusion, the immunohis-
tochemical data, in combination with the data obtained by the
in situ free-activin binding assay, show that bioactive activin
is present in the neointimal region of the atherosclerotic
vessel wall.
Expression of Activin, Follistatin, and Activin
Receptor mRNA in In Vitro–Activated SMCs
Our data obtained from the analysis of vascular specimens
demonstrated that the induction of activin in atherogenesis
was most prominent in neointimal SMCs and macrophages.
Medial SMCs present a contractile, fully differentiated phe-
notype, whereas the activated, atherosclerotic, neointimal
SMCs are proliferating and/or migrating entities. To mimic
this process in atherosclerosis in vitro, SMCs were subjected
to growth stimulation, and the expression levels of activin,
follistatin, and activin receptors were determined. SMCs were
obtained as explant cultures derived either from the iliac
artery (a muscular artery) or from the elastic aorta. Because of
the different phenotypic properties of SMCs, we chose to
culture the SMCs for 3 days in serum-free medium to induce
a quiescent, contractile phenotype. Subsequently, SMC pro-
liferation was stimulated by the addition of 20% human
serum to the culture. Then, total RNA was isolated from the
(un)stimulated SMCs and the RNA was subjected to RNase
protection analyses (Figure 5). In addition, RNase protection
analyses were performed using placenta RNA and tRNA as
the positive and negative controls, respectively.
For each riboprobe, the hybridizations were performed
simultaneously with a GAPDH riboprobe to verify the load-
ing of equal amounts of RNA (Figures 5b, 5d, 5f, 5h, and 5k).
Activin-bA mRNA expression (Figure 5a) in SMCs and
serum stimulation had no effect on activin-bA mRNA levels
in iliac artery SMCs, although in aortic SMCs, activin mRNA
was induced 2.5-fold. Notably, we found that follistatin
mRNA (Figure 5c) was downregulated 5-fold in serum-
stimulated iliac artery SMCs. This observation was also made
in aortic SMCs, although at relatively lower expression
levels. Activin-bB and inhibin-a expression were assayed,
but they could not be detected by RNase protection analysis.
It is conceivable that on atherogenic stimulation of SMCs, the
balance of follistatin and activin levels is shifted toward an
excess of free, bioavailable activin.
The expression level of ActR-I mRNA (Figure 5e) was
higher in iliac artery SMCs than in aortic SMCs; it was
Figure 2. mRNA expression of activin, follistatin, and activin
receptors in an early fibrotic aortic lesion containing ECs and
SMCs. Serial sections of an aortic lesion were analyzed by
immunohistochemistry (a through d) or radioactive in situ
hybridization (e through j) (see Materials and Methods). The rela-
tively small neointima on top of the media of the vessel wall is
shown in a. The boxed area of the neointima is shown in more
detail in b through j. The neointima is composed of SMCs (a
and b) and is lined at the luminal side with ECs (c). No macro-
phages were observed (d). Consecutive sections were analyzed
by in situ hybridization with specific probes for activin-bA (e),
follistatin (f), ActR-I (g), ActR-IB (h), ActR-II (i), and ActR-IIB (j).
Hybridization of the probes was visualized with epipolarization
microscopy, which resulted in bright blue dots on a pink back-
ground. All genes are expressed in ECs on top of the lesion.
Type I receptors show relatively low expression, whereas type II
receptors are expressed abundantly and homogeneously.
Activin, follistatin, and ActR-I show variable expression levels in
neointimal SMCs. L indicates lumen; M, media; Mf, macro-
phage; and NI, neointima. Original magnification 350 (a) or 3200
(b through j).
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decreased in serum-stimulated, iliac artery SMCs, but in
aortic SMCs, serum had no effect. RNase protection analyses
for ActR-IB (Figure 5g) showed an expression pattern similar
to that of ActR-I, although overall ActR-IB mRNA expres-
sion was less pronounced. ActR-II mRNA (Figure 5i) was
downregulated 5-fold in serum-stimulated, iliac artery SMCs;
aortic SMCs displayed less abundant ActR-II mRNA expres-
sion, which is not affected by the stimulation of these cells.
The expression of ActR-IIB mRNA (Figure 5j) was relatively
low and not substantially influenced by the different culture
conditions. These RNase protection analyses demonstrate that
SMCs express at least one type I receptor and one type II
receptor.
Activin Induces the Expression of SM a-Actin and
SM22a mRNA in SMCs
Arrested proliferation and the induction of differentiation in
SMCs coincides with a change from the activated and
proliferative phenotype into the nonactivated, contractile
phenotype of these cells. SMCs with a nonproliferative,
contractile phenotype express both the SM-specific variant of
a-actin (SM a-actin) and SM22a at high levels.24–27 To
assess the effect of activin on SMCs, we added purified
activin-A for 0, 3, 6, 12, and 24 hours to cultured SMCs
derived from the human aorta and iliac artery. In addition, the
SMCs were incubated with follistatin to block the activity of
endogenously synthesized activin. Subsequently, the expres-
sion of the differentiation markers SM a-actin and SM22a
was assayed by Northern blot analysis (Figure 6). Follistatin
had no effect on the expression of these markers in iliac artery
SMCs, but the expression of SM22a was reduced 2-fold in
aortic SMCs (Figure 6d), indicating that endogenous activin
contributes to the induction of SM22a expression in these
cells. Clearly, activin-A induces the expression of SMC-
specific markers. After 24 hours of activin treatment, a 2-fold
increase in SM a-actin expression was observed in aortic
SMCs (Figure 6b), whereas SM22a expression did not
change (Figure 6d). The activin treatment of iliac artery
SMCs had more pronounced effects: after 24 hours of
incubation, SM a-actin and SM22a mRNA levels increased
10-fold and 5-fold, respectively (Figures 6a and 6c). Collec-
tively, these observations demonstrate that activin promotes
the differentiation of proliferative SMCs into SMCs with a
nonproliferative, contractile phenotype.
Discussion
In this study, we determined, for the first time, the mRNA and
protein expression of both activin and follistatin in human
vascular tissue at different stages of atherosclerosis. These
experiments revealed the presence of activin-A in the normal
media, with a higher level of expression in the lesion;
follistatin was expressed at similar levels in the normal vessel
wall and in the atherosclerotic plaque. Activin and follistatin
colocalized to a large extent and, because follistatin can bind
and neutralize the biological activity of this growth factor, it
was essential to assess the presence of free, bioactive activin.
A newly developed, in situ free-activin binding assay allowed
us to selectively detect the presence of free activin in the
advanced atherosclerotic lesion, especially in areas rich in
both macrophages and neointimal SMCs. These results are
consistent with data obtained by in vitro studies, showing that
monocytic cells, upon differentiation into macrophages, and
growth-stimulated aortic SMCs produce more activin-bA
mRNA than nonactivated cells.3,28 At this point, it should be
added that neither in situ hybridization nor RNase protection
analyses revealed any expression of activin-bB and inhibin-a
transcripts, which excludes the possible presence of appre-
ciable amounts of activin-AB, activin-B, and inhibin in the
Figure 3. Differential mRNA expression
of activin and follistatin in an early lesion
(a through d) and an advanced lesion (e
through h) of the aorta. SMCs (a and e)
and macrophages (b and f) were
detected by immunohistochemistry with
specific antibodies (see Materials and
Methods). Consecutive sections were
analyzed for mRNA expression of
activin-bA (d and h) and follistatin (c and
g). Hybridization of probes was visual-
ized by dark-field microscopy, which
showed silver grains as white dots. In
early (a through d) and advanced lesions
(e through h), follistatin is expressed at
similar levels in the media in comparison
with the neointima (c and g), whereas
activin-bA expression is relatively higher
in the neointima than in the media (d and
h). L indicates lumen; M, media; Mf,
macrophage; and NI, neointima. Original
magnification 3200 (a through d), 350 (e
through h).
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vessel wall or in cultured SMCs. The exclusive expression of
the bA subunit in the human vasculature is reminiscent of the
situation in rat vessels, where also only activin-A expression
has been observed.17,29
We developed a free-activin binding assay to demonstrate
the presence of bioactive activin in situ. This assay is based
on the high-affinity interaction between follistatin and free
activin, which results in almost irreversible complex forma-
tion.30 Potential interactions of follistatin and bone morpho-
genetic proteins can be excluded because these interactions
are highly reversible, and such complexes will dissociate
during the procedure, which involves vigorous washing
steps.31 The mere presence of bioactive activin, especially in
the advanced atherosclerotic lesion, suggests a role for this
factor in the progression of the disease. A prerequisite for
functional involvement of activin in atherogenesis is, how-
ever, the presence of type I and type II activin receptors, as
well as downstream signaling components. Our RNase pro-
tection analyses on cultured SMCs and in situ hybridization
studies on vascular specimens demonstrated that SMCs, ECs,
and macrophages express at least one type I and one type II
receptor, which indicates that these cell types can bind activin
and probably also respond to activin. Because the expression
levels of activin receptors are similar in the media and in the
neointima, in contrast to a neointimal increase in bioactive
activin, activin function in atherogenesis seems to be regu-
lated by changes in expression levels of the soluble factor,
rather than by altered expression levels of its receptors.
Limited information is available on the signaling pathways
involved downstream of the activin receptors, except for the
binding and phosphorylation of the transcription factors
Smad2 and Smad3 by the activin-receptor complex. A com-
plex of these phosphorylated Smads and Smad4 is subse-
quently translocated to the nucleus of the activin-stimulated
cell to directly modulate the expression of, at present, mostly
unknown genes.10 Although the presence in vivo of activin
signal transduction pathway components, including the
Smads, needs to be confirmed, the demonstration of a
Figure 4. Immunohistochemical detection of activin-A and fol-
listatin combined with in situ free-activin localization. SMCs (a, f,
and k), macrophages (b, g, and l), follistatin protein (c, h, and
m), and activin-A protein (d, i, and n) were detected by applying
specific antibodies (see Materials and Methods). Activin that
was not bound to its receptor or to follistatin was detected by
the in situ free-activin binding assay using biotinylated follistatin
(e, j, and o). The assays were performed on subsequent cryo-
sections from an early aortic lesion (a through e; magnification
350) and different advanced aortic fibrous lesions (f through j;
magnification 325; k through o, magnification: 3630). In neointi-
mal areas containing both SMCs and macrophages, free, bioac-
tive activin was detected as a subpopulation of total activin pro-
tein. L indicates lumen; A, adventitia; M, media; and NI,
neointima.
Figure 5. Expression of activin, follistatin, and activin receptor
mRNA in SMCs, as determined by RNase protection assay. The
mRNA expression level of these genes was assayed in quies-
cent iliac artery SMCs (lane 1), serum-stimulated iliac artery
SMCs (lane 2), quiescent aortic SMCs (lane 3), and serum-
stimulated aortic SMCs (lane 4). In lane 5, the mRNA expression
in placenta is shown as a control. The probes were hybridized
with yeast tRNA (lane 6) to detect aspecific background bands.
The expression of the following genes was assayed in the
above-mentioned resting and stimulated SMCs: activin-bA (row
a), follistatin (row c), ActR-I (row e), ActR-IB (row g), ActR-II (row
i), and ActR-IIB (row j). Simultaneous hybridization with a
GAPDH riboprobe was performed for each of the gene-specific
probes as a control for equal loading (rows b, d, f, and h,
respectively). Because the expression of ActR-II, ActR-IIB, and
GAPDH was determined simultaneously, the GAPDH expression
data shown in row k were used to correct the quantitated data,
both for ActR-II and ActR-IIB. The radioactivity in the bands was
quantitated by PhosphorImager (Molecular Dynamics).
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physiologically relevant response of in vitro cultured cells on
activin treatment supports the in vivo significance of activin
in atherogenesis. Therefore, we will discuss the effect of
activin on the most relevant cell types involved in atherogen-
esis: ECs, SMCs, and macrophages.
First, in human ECs, activin and TGF-b inhibit DNA
synthesis,13 and we confirmed these observations (data not
shown). Second, in human SMCs derived from various
vascular origins, we showed that activin does not affect DNA
synthesis, whereas TGF-b does (data not shown). Also, in rat
SMCs, one study showed that activin does not influence DNA
synthesis,18 although these data contrast with results obtained
by other groups, which show increased DNA synthesis by
activin.16,17 To establish the physiological importance of
activin receptors on human SMCs and the presence of
functional signaling pathways, the effect of activin on SMC
differentiation was analyzed. In vitro cultured SMCs exhib-
ited a significant increase in mRNA expression of the
SM-specific markers SM22a and SM a-actin in response to
activin. The augmented expression of these genes is indica-
tive of SMC differentiation toward a nonactivated, fully
differentiated phenotype, which is commonly associated with
SMCs residing in the normal media or in the fully differen-
tiated fibrous cap of advanced lesions.24–27 In the present
study, we observed that iliac artery SMCs were more respon-
sive to activin than aortic SMCs, which may be attributed to
the relatively higher expression levels of ActR-I, ActR-IB,
and ActR-II in the iliac artery SMCs (Figure 5).
To our knowledge, this is the first study showing that
human SMCs originating from either the elastic aorta or the
muscular iliac artery differ in their response to a growth
factor. In this respect, it is of interest to note that chicken
vascular SMCs reportedly exhibit opposite growth responses
to TGF-b, depending on their embryonic origin (ectodermal
or mesodermal).32 These differences correlated with the
extent of glycosylation of the TGF-b type II receptors. At
present, it is not known whether activin receptors on human
SMCs of distinct vascular origin would be differentially
glycosylated, which could result in a different response
toward activin in elastic and muscular SMCs. Finally, in
human THP-1–derived macrophages, activin and TGF-b
inhibit scavenger receptor expression, resulting in reduced
lipid accumulation in these cells.15,33 This would suggest that
activin and TGF-b reduce atheroma foam cell formation
during atherogenesis.
The distinct responses of these 3 cell types to activin
illustrate the pleiotropic effects of this growth and differen-
tiation factor and may give an indication of the functional
involvement of activin in atherogenesis. It has been hypoth-
esized that plaque stability is inversely related to macrophage
and lipid content and is directly related to the number of
SMCs present in the lesion.34 By contrast, intimal SMCs are
thought to suppress plaque rupture and subsequent local
thrombosis, thereby preventing acute clinical problems. We
propose, on the basis of our knowledge that activin inhibits
foam cell formation in combination with our observations
that it induces the redifferentiation of vascular SMCs, that
activin, like TGF-b, may be beneficial for plaque stability.
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